Related Experiment Videos
NSAID sulindac and its analog bind RXRalpha and inhibit RXRalpha-dependent AKT signaling
1Institute for Biomedical Research, Xiamen University, Xiamen, Fujian 361005, China.
Abstract:
Nonsteroidal anti-inflammatory drugs (NSAIDs) exert their anticancer effects through cyclooxygenase-2 (COX-2)-dependent and independent mechanisms. Here, we report that Sulindac, an NSAID, induces apoptosis by binding to retinoid X receptor-alpha (RXRalpha). We identified an N-terminally truncated RXRalpha (tRXRalpha) in several cancer cell lines and primary tumors, which interacted with the p85alpha subunit of phosphatidylinositol-3-OH kinase (PI3K). Tumor necrosis factor-alpha (TNFalpha) promoted tRXRalpha interaction with the p85alpha, activating PI3K/AKT signaling. When combined with TNFalpha, Sulindac inhibited TNFalpha-induced tRXRalpha/p85alpha interaction, leading to activation of the death receptor-mediated apoptotic pathway. We designed and synthesized a Sulindac analog K-80003, which has increased affinity to RXRalpha but lacks COX inhibitory activity. K-80003 displayed enhanced efficacy in inhibiting tRXRalpha-dependent AKT activation and tRXRalpha tumor growth in animals.
Related Concept Videos
Antihypertensive Drugs: Direct Renin Inhibitors
The JAK-STAT Signaling Pathway
Drugs for Treatment of Ulcerative Colitis in IBD
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
Structure-Activity Relationships and Drug Design
SAR studies the intricate relationship between a drug's chemical structure and biological activity. It focuses on understanding how modifications to a drug's structure can influence its...
PI3K/mTOR/AKT Signaling Pathway